Reference health
Designer receptor technology for the treatment of epilepsy
72/72 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 72 checked references that resolve
resolves10.1016/j.yebeh.2018.06.037
Incidence rate of sudden death in epilepsy: A systematic review and meta-analysis
resolves10.1038/nm901
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion
resolves10.1093/brain/awn079
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy
resolves10.1523/JNEUROSCI.4056-03.2004
Anticonvulsant and Antiepileptogenic Effects Mediated by Adeno-Associated Virus Vector Neuropeptide Y Expression in the Rat Hippocampus
resolves10.1093/brain/awq219
Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures
resolves10.1126/scitranslmed.3004190
Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy
resolves10.1016/j.febslet.2015.05.004
Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability
resolves10.1038/ncomms2376
On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy
resolves10.1038/nn.3269
Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury
resolves10.1038/s41467-019-08933-4
KCC2 overexpression prevents the paradoxical seizure-promoting action of somatic inhibition
resolves10.1073/pnas.0700293104
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand
resolves10.1074/jbc.M112.423921
An Engineered Glutamate-gated Chloride (GluCl) Channel for Sensitive, Consistent Neuronal Silencing by Ivermectin
resolves10.1074/jbc.M110.107789
An Improved Ivermectin-activated Chloride Channel Receptor for Inhibiting Electrical Activity in Defined Neuronal Populations
resolves10.1126/science.1206606
Chemical and Genetic Engineering of Selective Ion Channel–Ligand Interactions
resolves10.1126/science.aav5282
Ultrapotent chemogenetics for research and potential clinical applications
resolves10.1073/pnas.95.1.352
Controlling signaling with a specifically designed G
<sub>i</sub>
-coupled receptor
resolves10.1016/S0021-9258(18)52392-9
Allele-specific activation of genetically engineered receptors.
resolves10.1016/j.neuron.2006.06.018
Selective and Quickly Reversible Inactivation of Mammalian Neurons In Vivo Using the Drosophila Allatostatin Receptor
resolves10.1016/j.neuron.2014.04.008
Chemogenetic Synaptic Silencing of Neural Circuits Localizes a Hypothalamus→Midbrain Pathway for Feeding Behavior
resolves10.1073/pnas.0906593106
A chemical-genetic approach to study G protein regulation of β cell function in vivo
resolves10.1124/mol.112.080358
Design and Functional Characterization of a Novel, Arrestin-Biased Designer G Protein-Coupled Receptor
resolves10.1016/j.neuron.2015.03.065
A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior
resolves10.1146/annurev-pharmtox-010814-124803
DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility
resolves10.1038/gt.2016.56
DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue
resolves10.1016/j.expneurol.2016.07.003
Chemogenetic silencing of the midline and intralaminar thalamus blocks amygdala-kindled seizures
resolves10.1038/s41598-018-23659-x
Dynamic interaction of local and transhemispheric networks is necessary for progressive intensification of hippocampal seizures
resolves10.1523/JNEUROSCI.3456-16.2017
Selective Silencing of Hippocampal Parvalbumin Interneurons Induces Development of Recurrent Spontaneous Limbic Seizures in Mice
resolves10.1172/JCI95731
Chemogenetic silencing of hippocampal neurons suppresses epileptic neural circuits
resolves10.3389/fncel.2018.00293
Chemogenetic Recruitment of Specific Interneurons Suppresses Seizure Activity
resolves10.1016/j.nbd.2018.06.006
Pharmaco-genetic therapeutics targeting parvalbumin neurons attenuate temporal lobe epilepsy
resolves10.1126/science.aan2475
Chemogenetics revealed: DREADD occupancy and activation via converted clozapine
resolves10.1016/j.biopsych.2006.09.023
Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports
resolves10.1021/cn500325v
The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs
resolves10.1021/acsptsci.8b00012
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs<i>in Vitro</i>and<i>in Vivo</i>
resolves10.1038/s41598-019-41088-2
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
resolves10.1126/sciadv.aaw1567
Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics
resolves10.1016/j.bcp.2013.07.001
Structural insights into Cys-loop receptor function and ligand recognition
resolves10.1111/epi.12797
Tonic glutamate in <scp>CA</scp>1 of aging rats correlates with phasic glutamate dysregulation during seizure
resolves10.1016/0140-6736(93)90754-5
Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain
resolves10.1523/JNEUROSCI.22-17-07373.2002
Selective Electrical Silencing of Mammalian Neurons<i>In Vitro</i>by the Use of Invertebrate Ligand-Gated Chloride Channels
resolves10.1113/JP275236
Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin
resolves10.1016/S0165-0270(02)00362-X
Codon optimization of Caenorhabditis elegans GluCl ion channel genes for mammalian cells dramatically improves expression levels
resolves10.1093/brain/awx201
Using an engineered glutamate-gated chloride channel to silence sensory neurons and treat neuropathic pain at the source
resolves10.1074/jbc.M011264200
Ivermectin, an Unconventional Agonist of the Glycine Receptor Chloride Channel
resolves10.3389/fnmol.2015.00055
Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors
resolves10.1016/S0022-3565(24)39005-6
Anticonvulsant and Adverse Effects of Avermectin Analogs in Mice Are Mediated through the γ-Aminobutyric AcidA Receptor
resolves10.4269/ajtmh.17-0042
Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
resolves10.1038/s41467-018-05843-9
Cas9 immunity creates challenges for CRISPR gene editing therapies
resolves10.1038/gt.2013.75
Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain
resolves10.1016/j.neuron.2017.04.016
Homeostatic Plasticity Shapes Cell-Type-Specific Wiring in the Retina
resolves10.1038/nrd4609
An analysis of the attrition of drug candidates from four major pharmaceutical companies
resolves10.1185/030079907X182185
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
resolves10.1111/j.1476-5381.2010.00682.x
Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
resolves10.1016/j.bbamem.2014.11.003
Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes
resolves10.1089/humc.2017.010
Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease
resolves10.1002/ana.25450
Magnetic resonance imaging–guided phase 1 trial of putaminal
<i>AADC</i>
gene therapy for Parkinson's disease
resolves10.1038/nature10139
Principles of activation and permeation in an anion-selective Cys-loop receptor
The 6 references without a DOI — listed, not checked
no DOI — not checkedChemogenetic silencing of excitatory hippocampal neurons prevents spontaneous seizures in a mosue model for temporal lobe epilepsy
no DOI — not checkedSelective elimination of glutamate activation and introduction of fluorescent proteins into a Caenorhabditis elegans chloride channel
no DOI — not checkedNicotine receptor partial agonists for smoking cessation
no DOI — not checked10.1016/j.ebiom.2019.04.059_bb0345
no DOI — not checked10.1016/j.ebiom.2019.04.059_bb0350
no DOI — not checked10.1016/j.ebiom.2019.04.059_bb0355
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ebiom.2019.04.059"><img src="https://citestamp.com/citestamped/10.1016/j.ebiom.2019.04.059/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ebiom.2019.04.059)